首页> 外文期刊>European journal of vascular and endovascular surgery: the official journal of the European Society for Vascular Surgery >The morphological applicability of a novel endovascular aneurysm sealing (EVAS) system (Nellix) in patients with abdominal aortic aneurysms
【24h】

The morphological applicability of a novel endovascular aneurysm sealing (EVAS) system (Nellix) in patients with abdominal aortic aneurysms

机译:新型血管内动脉瘤封闭系统(Nellix)在腹主动脉瘤患者中的形态学适用性

获取原文
获取原文并翻译 | 示例
           

摘要

Objective Endovascular aneurysm sealing (EVAS) using the Nellix system is a promising alternative to endovascular repair (EVR) and open surgery for abdominal aortic aneurysms (AAA). The aim of this study was to investigate the proportion of patients with AAA who are morphologically suitable for treatment with Nellix. Methods Patients presenting with AAA were investigated at two regionalised vascular units. Separate cohorts were identified, who had undergone infrarenal EVR, open aneurysm repair, fenestrated endovascular repair (FEVR) or non-operative management. Pre-operative morphology was quantified using three-dimensional computed tomography according to a validated protocol. Each aneurysm was assessed for compliance with the instructions for use (IFU) of Nellix Results 776 patients were identified with mean age 75 ± 9 years. 730/776 (94.1%) had undergone infrarenal EVR, 6/776 (0.8%) open repair, 27/776 (3.5%) FEVR and 13/776 (1.7%) had been managed non-operatively. 544/776 (70.1%) of all AAA were morphologically suitable for Nellix. 533/730 (73.0%) of patients who had undergone infrarenal EVR were compliant with Nellix IFU, compared with 497/730 (68.1%), 379/730 (51.9%) and 214/730 (29.3%) with the IFU for Medtronic Endurant (p =.04) or Cook Zenith (p <.01) and Gore C3 Excluder (p <.01) endografts respectively. Conclusions Nellix technology appears widely applicable to contemporary infrarenal AAA practice, and may provide an option for patients that are outside current EVR device instructions for use. However, formal outcomes study is still required, and will ultimately dictate the clinical relevance of this feasibility study. The major limitation to anatomic suitability for Nellix is currently the maximum patent lumen diameter of large AAA.
机译:目的使用Nellix系统进行血管内动脉瘤封闭(EVAS)是一种有希望的替代方法,可以替代血管内修复(EVR)和腹主动脉瘤(AAA)的开放手术。这项研究的目的是调查形态学上适合用Nellix治疗的AAA患者的比例。方法在两个区域性血管单位对出现AAA的患者进行调查。确定了分别接受过肾下EVR,开放性动脉瘤修复,开窗血管内修复(FEVR)或非手术治疗的人群。根据经过验证的方案,使用三维计算机断层扫描对术前形态进行定量。评估每个动脉瘤是否符合Nellix的使用说明书(IFU)。结果确定了776例患者,平均年龄为75±9岁。 730/776(94.1%)接受了肾下EVR,6/776(0.8%)进行了开放式修复,27/776(3.5%)的FEVR和13/776(1.7%)进行了非手术治疗。所有AAA的544/776(70.1%)在形态上都适合Nellix。接受肾下EVR的患者中533/730(73.0%)符合Nellix IFU,而Medtronic IFU的497/730(68.1%),379/730(51.9%)和214/730(29.3%) Endurant(p = .04)或Cook Zenith(p <.01)和Gore C3 Excluder(p <.01)内移植。结论Nellix技术似乎广泛适用于当代肾下AAA实践,并且可能为超出当前EVR设备使用说明的患者提供选择。但是,仍然需要正式的结果研究,并且最终将决定该可行性研究的临床意义。 Nellix对解剖学适用性的主要限制是目前大AAA的最大专利管腔直径。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号